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1 INTRODUCTION  
Acute agitation is a common and important clinical management problem in major psychotic and 
mood disorders such as schizophrenia, schizoaffective disorder and bipolar affective disorder, 
particularly in the manic phase of the latter (Nordstrom K, 2009, Sachs GS, 2006). Agitation is a 
poorly defined term generally used to describe excessive verbal or motor activity with a range of 
symptoms that may vary in intensity from mild to severe (Citrome L, 2004a, Nordstrom K, 2009, 
Schleifer JJ, 2011).  Allen (Allen MH, 2000) defines it as “a temporary disruption of the typical 
physician–patient collaboration, which interferes with assessment and treatment, during a 
period when immediate treatment is needed.”  As a lack of consensus in definition, agitation is 
often used interchangeably with the terms anxiety, hyperactivity, disruptive behaviour and non-
purposeful behaviour (Schleifer JJ, 2011).  Its hallmark features include motor restlessness, 
irritability, inappropriate or purposeless psychomotor activity and heightened responsivity to 
stimuli (Lindenmayer JP, 2000). It is distressing both emotionally and physically and severely 
agitated patients are at risk of causing harm to themselves and others. The intensity of agitation can 
rapidly escalate from mild to severe (Nordstrom K, 2009). Agitation, even when severe, does not 
necessarily entail aggression however, aggression is often preceded by agitation.  
 
The effective management of agitation is a key therapeutic target in the acute setting and for the 
longer-term care of patients with major psychiatric disorders. It impedes the assessment and 
evaluation of an acutely psychotic patient and the clinician will need to deal initially with the 
agitation before moving on to other aspects of treatment. Managing agitation effectively greatly 
improves patient outcomes, alleviates family burden and reduces societal costs. 
 
It is estimated that more than 90% of people with schizophrenia or bipolar disorder will 
experience agitation with an average of 12 episodes of acute agitation annually (National 
Institute for Health and Clinical Excellence, 2011). Lower levels of agitation are treated with 
psychological interventions aimed at reducing tension and anxiety. Behavioural approaches 
have also proven to be valuable and effective in reducing agitation. In the UK, the use of de-
escalation techniques have been formally recommended by the National Institute for Care and 
Clinical Excellence (NICE) to prevent situations that may lead to violence and 
aggression(National Institute for Health and Clinical Excellence, 2005). However, cases of 
severe agitation may require urgent pharmacological treatment to reduce potential risk to self 
and others when appropriate psychological and behavioural approaches have failed to de-
escalate acutely disturbed behaviour.  
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The pharmacological treatment of patients with agitation in individuals with psychiatric 
disorders is an area that is poorly researched and evidenced and there is currently wide 
variation in clinical practice (Brown S, 2011). Clinical guidelines by NICE for the treatment of 
schizophrenia (National Institute for Health and Care Excellence, 2014b) and bipolar disorder 
(National Institute for Health and Care Excellence, 2014a) do not make specific recommendations for 
the pharmacological management of acute agitation. In clinical practice antipsychotics, either typical 
(e.g. haloperidol) or atypical (e.g. risperidone and olanzapine) are used to treat acute agitation and are 
administered with or without supplemental benzodiazepines (e.g. lorazepam). These treatments may 
be given orally or intramuscularly.  
 
Our systematic review aimed to identify effective short-term pharmacological interventions that could 
be used for the management of agitation in patients with schizophrenia or bipolar disorder.  
 
2 METHOD 
2.1 Overview 
We conducted a systematic review of pharmacological interventions to treat agitation in people with 
psychosis (schizophrenia, schizophreniform disorder, schizoaffective disorder) and bipolar disorder. 
The main purposes of the review were to signpost those interventions that warrant further 
investigation and to highlight the gaps in the evidence base. The review was conducted in 
accordance with the PRISMA (Moher D et al., 2009) guidelines and the Centre for Reviews and 
Dissemination (CRD) published guidance on conducting systematic reviews in healthcare (Centre for 
Reviews and Dissemination, 2009). 
2.2 Search strategy 
The major electronic databases including Medline, EMBASE, PsycInfo and the Cochrane Library, 
were searched for relevant published literature. Searches were conducted for randomised 
controlled trials (RCTs) involving comparisons between current treatments for agitation and 
placebo. Search terms included a combination of index terms (e.g. agitation, aggression, 
violence, tranquilisation, psychotic disorders, schizophrenia, mood disorders, bipolar disorder 
and drug therapy or emergency treatment) and free text words (e.g. psychosis, bipolar, 
schizophrenia, antipsychotics and benzodiazepines) combined with specific drug terms 
including benzodiazepines (e.g. lorazepam, alprazolam, midazolam, clonazepam) and 
antipsychotics (e.g. haloperidol, risperidone, olanzapine, asenapine, ziprasidone). The database 
searches were conducted up to March 2015 and limited to English language. Reference lists of 
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retrieved articles were also searched to identify further studies (details of the search strategies 
used are available upon request). 
2.3 Inclusion and exclusion 
We (YD and JG) included RCTs that involved adults with agitation associated with psychotic or 
bipolar disorder according to ICD10 (1994b) (F20, F23, F25 and F31) or DSM IV(1994a) who were 
seen in specialist mental health services including in-patient and community mental health services. 
The interventions included a range of pharmacological treatments: oral, inhaled or intramuscular 
preparations (e.g. benzodiazepines (such as lorazepam) and antipsychotics (such as haloperidol, 
risperidone, olanzapine, ziprasidone and loxapine). The comparators were the aforementioned 
treatments compared with each other, placebo or no intervention. The outcomes of interest were 
agitation levels as measured by accepted standard scales (e.g. Positive and Negative Syndrome Scale 
Excited Component [PANSS-EC]), and adverse events (AEs), but these were not considered as 
inclusion criteria. 
We excluded RCTs that involved patients with psychotic presentations that were primarily due to 
medical conditions (including dementia) or substance misuse, and RCTs that measured agitation at 
24-hour intervals only. We also excluded dose-ranging trials in which there was no comparator 
intervention. 
2.4 Data extraction and quality assessment 
Data were extracted relating to trial design, intervention(s) used including dose and preparation type, 
participant characteristics and outcome measures taken. Missing data were requested from trial 
authors. 
2.5 Data analysis 
The trial characteristics, trial quality criteria and trial outcomes are summarised in Tables 1 and 2.  
2.6 Statistical analysis 
2.6.1 Paired meta-analysis 
A fixed effects model was used to combine the data at 60 minutes and 120 minutes for PANSS-EC 
score using RevMan (The Nordic Cochrane Centre, 2014) The mean difference and 95% confidence 
intervals are presented for each comparison. There were insufficient studies combined in order to 
construct a funnel plot to assess publication bias, conduct subgroup analyses or sensitivity analyses. 
Heterogeneity was assessed by visually assessing the forest plots, the I
2
 statistic (Higgins et al., 2003) 
and Chi-squared (p<0.1). 
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2.6.2 Network meta-analysis 
The analyses were conducted using WinBugs version 1.4. The control and intervention effect 
parameters were given flat (uninformative) Normal (0, 1000) priors and the standard deviation flat 
Uniform distributions with an appropriately large range given the scale of measurement. Fixed and 
random effects models were investigated for the network meta-analysis. The deviance information 
criterion statistic and the total residual deviance were observed to ensure that the model’s overall fit 
was adequate. In all cases a burn in of at least 30,000 simulations were discarded. All results 
presented are based on a further sample of 50,000 simulations. 
As both fixed effects and random effects models were investigated, it was necessary to consider the 
Deviance Information Criterion (DIC) and total residual deviance values for each model, in order to 
decide which would be the most appropriate to fit the data. The value of the total residual deviance 
should be as close to the number of data points as possible, while smaller DIC values indicate better 
model fit.  
3 RESULTS 
The literature searches yielded 1798 hits; 105 were selected for full text review and application of 
inclusion/exclusion criteria. A total of 17 RCTs were selected for inclusion in the review.  
3.1 Characteristics of included trials and participants 
The key trial and participant characteristics are described in Table 1. The 17 RCTs (Allen et al., 2011, 
Andrezina et al., 2006, Breier et al., 2002, Currier et al., 2004, Fang et al., 2012, Hsu et al., 2010, 
Hwang TJ et al., 2012, Katagiri H. et al., 2013, Kinon et al., 2004, Kwentus et al., 2012, Lesem et al., 
2011, Lim et al., 2010, Meehan et al., 2001, Tran-Johnson et al., 2007, Wright et al., 2001, Zhang et 
al., 2013, Zimbroff et al., 2007) recruited a combined total of 3841 patients. The majority of the trials 
included only patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, 
whilst three trials (Kwentus et al., 2012, Meehan et al., 2001, Zimbroff et al., 2007)  included only 
patients with bipolar disorder. Three trials included patients with schizophrenia or bipolar disorder 
(Currier et al., 2004, Hsu et al., 2010, Lim et al., 2010).  The numbers of patients recruited to each 
trial ranged from 42 (Hsu et al., 2010) to 448(Andrezina et al., 2006). 
The trials were published between 2001 and 2013 and the mean ages of the participants across the 
trials ranged from 32 years to 47 years. Three trials included a substantially higher percentage of 
males compared to females.(Allen et al., 2011, Kinon et al., 2004, Lesem et al., 2011)  
A range of interventions and comparators were employed. The most frequently investigated treatment 
was haloperidol monotherapy (Andrezina et al., 2006, Breier et al., 2002, Fang et al., 2012, Kinon et 
al., 2004, Lim et al., 2010, Tran-Johnson et al., 2007, Wright et al., 2001, Zhang et al., 2013). 
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Olanzapine was used in six trials (Breier et al., 2002, Hsu et al., 2010, Katagiri H. et al., 2013, Kinon 
et al., 2004, Meehan et al., 2001, Wright et al., 2001),  aripiprazole featured in three trials (Andrezina 
et al., 2006, Tran-Johnson et al., 2007, Zimbroff et al., 2007),  loxapine in three trials (Allen et al., 
2011, Kwentus et al., 2012, Lesem et al., 2011),  risperidone monotherapy was utilised in two trials 
(Hsu et al., 2010, Lim et al., 2010) and lorazepam monotherapy in two trials.(Meehan et al., 2001, 
Zimbroff et al., 2007). Three trials employed a combined treatment approach: one assessed the use of 
risperidone with lorazepam (Currier et al., 2004),  one risperidone with clonazepam (Fang et al., 
2012) and two trials used haloperidol with lorazepam(Currier et al., 2004, Hwang TJ et al., 2012). The 
trials assessing inhaled loxapine (Allen et al., 2011, Kwentus et al., 2012, Lesem et al., 2011) all 
included two dose sizes of loxapine (5mg and 10mg), a range of dose sizes of olanzapine were 
included in another trial (Breier et al., 2002) whilst a range of doses of aripiprazole were included in a 
third trial (Tran-Johnson et al., 2007). 
In the majority of the included trials, the protocol prescribed that up to three doses of medication 
could be given across a 24-hour period with at least 2 hours between any subsequent doses. The 
exceptions to this were the Fang (Fang et al., 2012) and Hsu (Hsu et al., 2010) trials in which a single 
daily dose of trial drug was given. 
The majority of the trials were conducted over a 24-hour period; the exceptions were Fang (5 days), 
Kinon (3 weeks) and Zhang (72 hours). The latter three trials were included in the review as agitation 
was measured at regular timepoints during the first 24 hours.  
The dose sizes and method of administration of the interventions were consistent across the inhaled 
loxapine trials (Allen et al., 2011, Kwentus et al., 2012, Lesem et al., 2011), however, the dose sizes 
and method of administration across the remainder of the trials varied.  Aripiprazole was administered 
in an intramuscular (IM) formulation with doses ranging between 1mg and 15mg. Haloperidol was 
administered as an IM formulation at single doses ranging between 5mg and 7.5mg and in an oral 
formulation of 10mg. Three different formulations of olanzapine were employed, IM (doses ranging 
between 2.5mg and 10mg) ODT (10mg) and oral (10mg). Risperidone was given orally at 2mg or (2-
6 ml) either alone, or with lorazepam or clonazepam. In the single trial using ziprasidone, treatment 
was administered as IM at 10 to 20mg. Where lorazepam was employed as a comparator, it was given 
IM at 2mg.  
The primary outcome of the majority of trials was change in the excited component of the Positive 
and Negative Syndrome Scale (PANSS-EC) from baseline either as measured at 2 hours or 24 hours. 
The PANSS-EC scale measures five symptoms associated with agitation: poor impulse control, 
tension, hostility, uncooperativeness and excitement. Each symptom is rated on a scale of 1 (absent) 
to 7 (extreme), and scores are summed. Therefore, total scores can range from 5 (all symptoms 
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absent) to 35 (all symptoms extreme). The mean baseline agitation scores across all trials as measured 
by PANSS-EC ranged from 12.69 (Meehan et al., 2001) to 26 (Hsu et al., 2010). All trials with 
PANSS-EC as a primary outcome had specified that included patients should have a score of at least 
14; however, participants in the Meehan (Meehan et al., 2001) trial had a mean agitation score of 
12.69. The time intervals of the measurement of PANSS-EC varied across trials.  
Three trials did not use the PANSS-EC scale as a measure of agitation. One trial (Currier et al., 2004) 
reported a primary outcome as 5 items from PANSS (excitement, hostility, uncooperativeness, 
hallucinatory behaviour,  poor impulse control) and another (Kinon et al., 2004) as the reduction in 
PANSS agitation 10-item subscale. One trial reported the primary outcome as change from baseline 
on the Brief Psychiatric Rating Scale (BPRS) at 72 hours (Zhang et al., 2013). The trial measuring 
agitation using a 10 item agitation subscale of the PANSS reported mean baseline scores of 37.74 
(Kinon et al., 2004). The trial measuring agitation on the BPRS scale reported a mean baseline score 
of 56.6.   
All trials reported a range of secondary outcomes. These included (but were not limited to) the 
Clinical Global Impressions Scale (CGI), Agitation-Calmness Evaluation Scale, Brief Psychiatric 
Rating Scale, Overt Aggression Scale, Behavioural Activity Rating Scale and PANSS overall scale. 
All trials with the exception of Hsu (Hsu et al., 2010) were funded by pharmaceutical companies. 
3.2 Quality assessment 
Quality assessment of the included trials was conducted in accordance with the CRD published 
guidance (Centre for Reviews and Dissemination, 2009). The assessment criteria include six main 
quality domains: randomisation, comparability of participants, eligibility criteria, blinding procedures, 
participant withdrawals and outcome reporting bias. Each item is scored as either yes, no, not stated, 
not applicable or unclear.    
Only four of the included trials (Andrezina et al., 2006, Kwentus et al., 2012, Lesem et al., 2011, Lim 
et al., 2010) provided sufficient information for the randomisation procedures and allocation 
concealment to be assessed. With the exception of the Hwang (Hwang TJ et al., 2012) trial (abstract 
only available) all trials reported details of numbers of participants, their baseline comparability and 
the eligibility criteria for inclusion in the trial. For the most part, participant characteristics were 
comparable between trial arms. The majority of trials reported the use or potential use of co-
medication, such as rescue treatments (generally lorazepam) or treatments for extra-pyramidal 
symptoms. In the trials that included blinding, it was not always apparent who was blinded. One trial 
reported assessing the blinding procedures (Lesem et al., 2011). In 11 trials, the participants were 
reported to be blinded to their treatment assignment (Allen et al., 2011, Andrezina et al., 2006, Breier 
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et al., 2002, Katagiri H. et al., 2013, Kinon et al., 2004, Kwentus et al., 2012, Lesem et al., 2011, 
Meehan et al., 2001, Tran-Johnson et al., 2007, Wright et al., 2001, Zimbroff et al., 2007) All trials 
appeared to include at least 80% of participants in the final analyses. In all cases where appropriate, 
the last observation carried forward method was used to compensate for patient losses. No trial 
appeared to report fewer outcomes than were measured. 
3.3 Clinical outcomes 
In this review we focus on the outcomes of PANSS-EC and AEs of treatment. The PANSS-EC 
outcome was measured at different time points across the trials. The author conclusions for individual 
trials are reported in Table 2. 
The AEs were reported differently across the included trials. We report (Table 2) the number and 
percentage of any treatment-related AEs and numbers of patients who withdrew from the trial due to 
AEs. The AEs included headache, dizziness, sleep problems, hypotension, sedation, extra-
pyramidal symptoms. 
3.4 Pairwise meta-analysis 
3.4.1 Olanzapine versus halop ridol 
Four trials (Breier et al., 2002, Hsu et al., 2010, Kinon et al., 2004, Wright et al., 2001) investigated 
this comparison, (n= 465). However, only three trials (Breier et al., 2002, Hsu et al., 2010, Wright et 
al., 2001) (n=365) reported data for change in PANSS-EC scores at 60 and 120 min.  Kinon (Kinon et 
al., 2004) did not report this outcome.  At 60 minutes, the mean difference was -3.64 (95% CI: -6.90, -
0.38) indicating a statistically significant difference in change in PANSS-EC score at 60 minutes 
favouring olanzapine, although this was only based on one small trial (n=22).  There was no 
significant difference at 120 minutes (MD -0.65 [95% CI:-1.76, 0.46]). Only Kinon (Kinon et al., 
2004) and Hsu (Hsu et al., 2010) reported AEs. The risk ratio was not significant (0.91 [95% CI: 0.73, 
1.14]) indicating no difference between the treatments. 
3.4.2 Loxapine inhaled 5mg versus loxapine inhaled 10mg 
Three trials (Allen et al., 2011, Kwentus et al., 2012, Lesem et al., 2011) investigated this comparison, 
(n=524) and all reported data for change in PANSS-EC scores at 60 and 120 min and AEs. The mean 
difference in change in PANSS-EC scores at 60 minutes was not statistically significant although the 
results appear to favour loxapine 10mg (MD 0.79 [95% CI: -0.01, 1.59]).  At 120 minutes, the 
difference is statistically significant (MD 0.87 [95% CI: 0.04, 1.69]).  The change in PANSS-EC 
score is 0.87 more on 10mg compared to 5mg. For AEs, the risk ratio was not significant (0.99 [95% 
CI: 0.78, 1.25]), indicating no difference between the treatments. 
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3.4.3 Haloperidol versus risperidone 
Two trials (Hsu et al., 2010, Lim et al., 2010) investigated this comparison (n=145) but only one trial 
(Hsu et al., 2010) (n=21) reported data for change in PANSS-EC scores, 60 and 120 min . Both 
studies reported data for AEs. The mean difference in the change in PANSS-EC scores at both 60 and 
120 minutes was not statistically significant, MD 2.25 (95% CI:-0.61, 5.11) and 0.63 (95% CI: -2.17, 
3.43). For AEs, the risk ratio was not significant (0.59 (95% CI: 0.31, 1.11)), indicating no difference 
between the treatments. 
3.4.4 Olanzapine versus lorazepam 
One trial (Meehan et al., 2001) investigated this comparison, (n=150) and reported data for change in 
PANSS-EC scores at 120 min and AEs. The mean difference in the change in PANSS-EC scores at 
120 minutes was statistically significant, MD -2.85 (95% CI: -4.56, -1.14).  The change in PANSS-EC 
scores is 2.85 more on olanzapine compared to lorazepam. For AEs, the risk ratio was significant 
(0.67 [95% CI: 0.46, 0.9]), indicating a 33% reduction in risk of AEs for olanzapine compared to 
lorazepam.  
3.4.5 Aripiprazole versus lorazepam 
One trial (Zimbroff et al., 2007) investigated this comparison (n=148) but did not report any data for 
change in PANSS-EC scores at 60 and 120 min. Zimbroff  (Zimbroff et al., 2007) reported overall 
AEs not AEs by treatment group. 
3.4.6 Haloperidol versus risperidone plus clonazepam 
One trial (Fang et al., 2012) investigated this comparison, (n=162 but only data for change in PANSS-
EC scores, 120 min and AEs are reported. The mean difference in the change in PANSS-EC scores at 
120 minutes was not statistically significant, MD -0.50 (95% CI: -2.90, 1.90). For AEs, the risk ratio 
was significant (1.72 [95% CI: 1.29, 2.29]), indicating a 72% increase in risk for haloperidol 
compared to risperidone plus clonazepam. 
3.4.7 Haloperidol versus aripiprazole 
Two trials (Tran-Johnson et al., 2007) investigated this comparison (n=465) but only Andrezina 
(Andrezina et al., 2006) reported data for change in PANSS-EC scores at 60 and 120 min. Both trials 
report AEs, but Andrezina (Andrezina et al., 2006) appears to only report serious AEs. The mean 
differences in the change in PANSS-EC scores at 60 and 120 minutes were not statistically 
significant, MD -0.90 (95% CI: -2.42, 0.62) and MD -0.48 (95% CI: -2.11, 1.15), respectively. For 
AEs and serious AEs, the risk ratios were not significant (0.91 [95% CI: 0.61, 1.35]) and 1.06 (95% 
CI: 0.27, 4.16)), indicating no difference between the treatments. 
Page 9 of 37
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Pharmacological treatment of agitation 
  Page 10 of 16 
 
3.4.8 Risperidone and lorazepam versus haloperidol and lorazepam 
One trial (Currier et al., 2004) investigated this comparison (n=162) but no data for change in 
PANSS-EC scores at 60 and 120 min or AEs were reported. 
3.4.9 Olanzapine versus haloperidol and lorazepam 
One trial (Hwang TJ et al., 2012) investigated this comparison (n=67) but only reported data for 
change in PANSS-EC scores at 120 min. The mean difference in the change in PANSS-EC scores at 
120 minutes was not statistically significant, MD -0.20 (95% CI: -3.10, 2.70). No data were reported 
for AEs. 
3.4.10 Interventions versus placebo 
Nine of the included trials (Allen et al., 2011, Andrezina et al., 2006, Breier et al., 2002, Katagiri H. et 
al., 2013, Kwentus et al., 2012, Lesem et al., 2011, Meehan et al., 2001, Tran-Johnson et al., 2007, 
Wright et al., 2001) compared interventions to a placebo arm.  
3.5 Network meta-analysis 
Assessing model fit 
As a lower DIC value was observed for fixed effects than random effects for data at both 60 
minutes (DIC=96.705 and DIC=97.517 for fixed effects and random effects, respectively) and 
120 minutes (DIC=194.647 and DIC=196.004 for fixed effects and random effects, respectively), 
it was decided that the fixed effects models were the most suitable. 
 
Inconsistency 
DIC and total residual deviance values, show that the fixed effects model fits the data very well 
(DIC 96.705, total residual deviance 11.02 for the data measured at 60 mins, and DIC 194.647, 
total residual deviance 20.06 for the data measured at 120 mins), and therefore there is no 
evidence that inconsistency between direct and indirect estimates of treatment effects may exist.  
 
Results 
None of the results from the network meta-analysis are statistically significant (Table 3).  However, 
the confidence intervals are very wide due to the small sample sizes so it may be that there are 
differences in treatment effects but there is not enough statistical power to detect them. At 60 minutes 
olanzapine has the highest probability of being best (29.08%), followed by risperidone (17.72%), 
and loxapine 10 mg (17.45%). At 120 minutes risperidone plus clonazepam has the highest 
probability of being best (27.68%), followed by haloperidol plus lorazepam (22.88%), and 
aripiprazole (16.42%).  
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4 DISCUSSION 
Main findings 
We included 17 RCTs (3841 participants) that assessed pharmacological interventions for people with 
agitation associated with schizophrenia or bipolar disorder. The majority of the trials used the 
PANSS-EC as a measure of agitation. We focussed on the outcome measured at 60 minutes and 120 
minutes as those time intervals were most frequently reported. We also consider that these time 
intervals are of key interest to clinicians. 
Of the trials that compared active treatment with placebo, the active treatment was found to be 
superior in all but the comparison of haloperidol versus placebo at 120 minutes. Appropriate use of 
de-escalation techniques may increase the placebo effect and partly explain the non-significant 
differences found in a number of trials comparing active pharmacological intervention versus 
placebo. However, in our view, the most useful information for clinicians is whether one treatment is 
more effective than another. The pair-wise comparisons suggest that after 60 minutes, olanzapine is 
superior to haloperidol; no other treatment (where comparisons were available) was more effective 
than any other. At 120 minutes, loxapine 10mg was found to be more effective than loxapine 5mg and 
olanzapine more effective than lorazepam.  
The results of our NMA did not demonstrate any treatment was more effective than any other. 
However, the results of the NMA indicate that at 60 minutes, treatment with olanzapine has the 
greatest possibility to be the most effective treatment and at 120 minutes, treatment with risperidone 
plus clonazepam has the greatest possibility to be the most effective treatment.  
In terms of AEs, our review noted a reduction in risk in favour of olanzapine when compared with 
lorazepam and a substantial increase in risk for haloperidol when compared with clonazepam. 
Strengths and limitations 
To our knowledge, this is the first systematic review in this clinically important area and in this 
patient group.  Our review compares the efficacy of all pharmacological treatments used in patients 
with agitation associated with schizophrenia or bipolar disorder. We did not include patients with 
agitation seen in emergency departments of hospitals and who required rapid tranquilisation for 
aggression or agitation, or patients with agitation associated with other conditions. Existing Cochrane 
Reviews (Ahmed et al., 2010, Gillies et al., 2013, Powney et al., 2012) have considered specific 
pharmacological interventions (benzodiazepines, haloperidol, chlorpromazine) for the treatment of 
aggression or agitation associated with psychosis in patients requiring rapid tranquilisation.  
The results from our review must be interpreted with considerable caution. The aim of the review was 
to identify the most effective pharmacological treatments available for use in appropriate patients with  
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schizophrenia or bipolar disorder who experience agitation. It is difficult to reach any conclusion 
based on the trials available for inclusion in our review. 
A number of factors presented challenges to the data extraction and synthesis processes of our review. 
A range of treatments and comparisons were reported across the 17 trials, including combinations of 
treatment.  In addition, different treatment doses were employed across the trials and different 
methods of treatment administration were used, oral, intra-muscular, ODT and inhaled. The majority 
of trials assessed the reduction of agitation measured by changes in PANSS-EC scores, however 
PANSS-EC measurements were taken at a variety of time intervals across the trials.  
The methodological quality of all of the included trials is questionable, for example, only four trials 
reported any information regarding the randomisation procedures used. It is notable that the RCTs 
rated as being of the highest quality were those involving the use of loxapine. We have concerns 
about the lack of any blinding procedures in the majority of trials and the small numbers of patient 
numbers recruited to the trials, ranging from 42 to 448. It is uncertain whether these limited sample 
sizes would be sufficiently powered to detect treatment differences. All trials with PANSS-EC as a 
primary outcome specified that included patients should have a score of at least 14, mean baseline 
agitation scores across all (Bhandari M et al., 2004, Rochon PA et al., 1994) trials ranged from 12.69 
(Meehan et al., 2001) to 26 (Hsu et al., 2010). We do not know if the patients in the trials are 
representative of patients in clinical practice who would be considered for pharmacological treatment. 
It has been documented elsewhere that severely agitated patients are excluded from clinical trials due 
to their inability to provide informed consent (Centorrino et al., 2007). We also note that the PANSS-
EC scale is used only as a measure in clinical trials and is not used in clinical practice. Our review 
relies on the use of PANSS-EC, a surrogate measure of an ill-defined and poorly understood mental 
health event. The outward signs of agitation may vary between disorders and cultures (Montoya et al., 
2011). 
A further significant reason for caution is that all but one of the trials included in our review was 
conducted with pharmaceutical company support, a factor known to cause bias in reported studies 
(Bhandari M et al., 2004, Flacco et al., Rochon PA et al., 1994). 
Of great importance to patients and clinicians is the issue of AEs of treatment. We encountered 
difficulties with extracting data from the trial publications. These difficulties were due to the 
inconsistent reporting of AEs across the included trials. Not all trials reported on AEs of treatment. 
We consider the lack of clarity in the reporting of AEs a matter of concern as patient safety, 
particularly in the area of patient mental health is a key consideration. We acknowledge that safety 
information is available in the relevant Summary of Product Characteristics for each drug. 
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Clinical implications 
Due to limitations of available research, we are unable to quantify the clinical value of any of the 
treatments included in our review. No firm conclusions can be drawn regarding the efficacy and 
safety of any of the interventions reviewed and there are clear research needs in this area. We found 
no consistent pattern of superiority of one treatment over another. Consideration should therefore 
be given to a sufficiently large, non-commercially supported, good quality trial to allow direct 
comparisons of key treatments. The trial should be sufficiently powered to detect treatment 
differences in a well-defined patient group.  In addition, the reporting of AEs must be clear and be of 
value to clinicians and patients. A particularly valuable component of any new trial would be a quality 
of life outcome and a qualitative review. The latter would give important insights into patients’ 
perceptions of and satisfaction with their treatment. 
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Table 1 Trial characteristics 
Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Allen 
2011 
 
N=129 
 
Loxapine Inhaled 10mg 
(n=41) 
Loxapine Inhaled 5mg 
(n=45) 
Placebo Inhaled 
(n=43) 
105 (81) 
 
 
 
 
Parallel double blind 
placebo controlled trial 
 
18 centres in USA 
Alexza 
Pharmaceuticals 
 
(4 authors with 
financial interest in 
Alexza 
Pharmaceuticals 
and 2 authors 
employed by 
Novartis) 
Change from baseline on 
PANSS-EC measured 2 
hours post-intervention 
 
 
• ≥ 18 and ≤65 years  
• DSM-IV criteria for 
schizophrenia, 
schizophreniform disorder or 
schizoaffective disorder 
• clinical agitation defined as 
PANSS-EC  ≥14 with at least 
1 item ≥4 
 
24 hours 
Andrezina 
2006 
N=448 
 
Aripiprazole IM 
9.75mg up to 3/day(max 
29.25mg during IM 
treatment); (n=175) 
 
Haloperidol IM  
6.5mg up to 3/day(max 
1.95mg during IM 
treatment); (n=183) 
 
Placebo (n=87) 
 
 
110 (63)
 
 
 
 
 
109 (59)
  
 
 
 
 
55 (63)
  
Parallel double blind 
placebo controlled  trial 
 
USA (68 centres) 
 
 
Bristol-Myers 
Squibb and Otsuka 
Pharmaceutical  
 
(1 author 
employed by 
Bristol-Myers 
Squibb , 2 authors 
employed by 
Otsuka 
Pharmaceutical) 
Change from baseline on  
PANSS-EC  measured 2 
hours post-intervention 
 
 
• ≥ 18 years  
• DSM-IV criteria for 
schizophrenia or 
schizoaffective disorder 
evidence of clinical agitation 
during screening period 
defined as PANSS-EC  ≥15 
and ≤32 with at least 2 items 
≥4 
 
24 hours 
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Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Breier 
2002 
N=270 
 
Olanzapine IM 2.5mg up to 
3/day; (n=48) 
 
Olanzapine IM 5.0mg up to 
3/day; as above (n=45) 
 
Olanzapine IM 7.5mg up to 
3/day; as above (n=46) 
 
Olanzapine IM 10.0mg up 
to 3/day as above (n=46) 
 
Haloperidol IM 7.5mg up to 
3/dayas above (n=40) 
 
Placebo IM  (n=45) 
 
 
31 (64.6) 
 
 
27 (60.0) 
 
 
26 (56.5) 
 
 
26 (56.5) 
 
 
22 (55.0) 
 
 
23 (51.1) 
Parallel double blind 
placebo controlled trial 
 
Europe and South 
Africa (14 centres), 
setting not reported 
 Eli Lilly and Co  
 
(10 of 12 authors 
employed by Eli 
Lilly and Co.) 
Change from baseline on 
PANSS-EC measured 30, 
60 and 90 minutes and 2, 
4, 6, 12, and 24 hours 
post-intervention 
 
 
• ≥ 18 years  
• DSM-IV criteria for 
schizophrenia, 
schizophreniform disorder or 
schizoaffective disorder 
• evidence of clinical agitation 
during screening period 
defined as PANSS-EC  ≥14 
with at least 1 item ≥4 
 
24 hours 
Currier  
2004 
N=162 
 
Risperidone (2mg) 
+lorazepam (2mg)  (oral) 
N= 83 
 
Haloperidol IM (5mg) + 
lorazepam IM (2mg) 
N=79 
 
 
56 (67) 
 
 
 
49 (62) 
 
Rater-blinded RCT 
 
USA (24 sites) 
emergency 
department/hospitalised 
patients 
 
Janssen 
Pharmaceutical  
 
(4 of the authors 
were employed by 
Janssen 
Pharmaceutical) 
Change from baseline on 
5 items from PANSS 
(excitement, hostility, 
uncooperativeness, 
hallucinatory behaviour, 
poor impulse control) 
measured 30 minutes, 1, 
2, 3, 6 and 24 hours post-
intervention 
• 18 to 65 years 
• DSM-IV criteria for acute 
exacerbation of 
schizophrenia, 
schizoaffective disorder, 
mania with psychotic 
features, acute paranoid 
reaction, delusional disorder 
• score  ≥ 14 on the PANSS 
and ≥3 on CGI-S 
24 hours 
Fang  
2012 
N=205 
 
Risperidone oral 2-6 ml 
plus Clonazepam 0-8 mg 
per day (n=104) 
 
Haloperidol IM 10-20mg per 
day (n=101)  
48 (46.2) 
 
32.3 (9.4) 
 
 
 
31.7 (9.2) 
Parallel, open-label  
 
China (6 centres) 
 
Xian-Janssen 
Pharmaceutical Ltd 
Primary: 
Change from baseline on 
PANSS-EC measured at  
2, 4, and 24 hours post-
intervention during first, 
third and fifth day 
 
 
• 18 to 45 years  
• DSM-IV criteria for acute 
exacerbation of 
schizophrenia or 
schizoaffective disorder, 
• score ≥ 14 on the PANSS 
EC and ≥60 on PANSS 
5 days  
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Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Hsu 2010 N=42 
 
Olanzapine IM 10mg 
(n=11) 
Olanzapine ODT 10mg 
(n=10) 
Risperidone oral 3mg 
(n=10) 
Haloperidol IM 7.5mg 
(n=11)l 
20 (49) 
 
6 (55) 
 
6 (60) 
 
3 (33) 
 
5 (45) 
Parallel, rater-blinded 
 
Taiwan (single centre) 
Inpatients 
None Change from baseline on 
PANSS-EC over 24 hours 
 
 
• 18 to 65 years 
• DSM-IV criteria for 
schizophrenia or 
schizoaffective disorder, 
bipolar 1 disorder, delusional 
disorder, other psychotic 
disorders 
• score  ≥ 14 on the PANSS 
EC with ≥4 on at least one 
item 
24 hours 
Hwang 
2013  
N=67 
Olanzapine IM 10mg  
(n=37) 
 
Haloperidol IM 5 mg and 
Lorazepam IM 2mg 
(n=30) 
Not 
reported 
Single-blind, parallel, 
multicenter  
 
China, hospital 
None reported Change from baseline 
PANSS-EC score over 2 
hours   
 
  
Recently hospitalised acutely 
agitated patients 
with schizophrenia or 
schizoaffective disorder 
 
24 hours 
Katagiri 
2013 
N=90 
 
Olanzapine IM 10mg 
(n=45) 
 
Placebo IM 
(n=44) 
 
 
21 (47) 
 
23 (51) 
Double-blind, parallel-
group, multicenter 
 
Japan, outpatients 
(requiring 
hospitalization) and 
inpatients  
Eli Lilly Change from baseline on 
PANSS-EC over 2 hours  
 
 
• 20 to 65 years 
• DSM-IV-TR criteria for 
schizophrenia 
• ACES score of 1 or 2 
 
 
24 hours 
Kinon 
2004 
N=100 
 
Olanzapine oral  (n=52) 
 
Haloperidol  (n=48) 
 
 
 
71% 
 
71% 
 
Parallel, double-blind, 
multicentre 
 
USA, inpatients 
Eli Lilly Change in PANSS 
Agitation score at 1, 4, 8, 
16 and 24hrs after 
treatment initiation and 
then daily for the first 
week and weekly until 3 
week study completion 
• 18 to 50 years 
• schizophrenia, 
schizophreniform disorder or 
schizoaffective disorder  
• PANSS Agitation subscale 
score ≥20 and CGI-S score 
≥4 
3 weeks 
Kwentus 
2012 
N=314 
 
Loxapine inhaled 5mg 
(n=104) 
 
 
47 (45) 
53 (51) 
Double blind placebo 
controlled, parallel 
 
USA (17 centres), 
Alexza 
Pharmaceuticals (4 
authors were 
consultants to 
Change from baseline in 
the PANSS-EC score 2 
hours after dose 1 
 
• 18 to 65 years 
• DSM-IV criteria for bipolar 
• I disorder, with either manic 
or mixed episodes 
24 hrs 
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For Peer Review
Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Loxapine inhaled 10mg 
(n=105) 
Placebo inhaled (n=105) 
56 (53) 
 
hospital Alexza and 3 
others were 
employees of 
Alexza. The 
employees all held 
Alexza stock and 
stock options) 
 • PANSS-EC Agitation 
subscale score ≥14 and ≥4 
on at least 5 items 
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Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Lesem 
2011 
N=344 
 
Loxapine inhaled  5mg 
(n=116) 
  
Loxapine inhaled  10mg 
(n=113) 
 
Placebo (n=115)  
 
 
87(75) 
 
 
86(76) 
 
 
80(70) 
Double blind placebo 
controlled, parallel 
 
USA (24 centres), 
hospital 
Alexza 
Pharmaceuticals  
 
(5 authors were 
consultants to or 
employees of 
Alexza 
Pharmaceuticals) 
Change from baseline in 
the PANSS-EC score 2 
hours after first dose 
 
 
• 18 to 65 years 
• DSM-IV criteria for 
schizophrenia 
• PANSS-EC score ≥14 with a 
score of  ≥4 on at least 5 
items 
24 hrs 
Lim 2010 N=124 
 
Risperidone ODT 2mg 
(n=62) 
 
Haloperidol IM 5mg (n=62) 
 
 
34 (55) 
 
32 (52) 
 
Open label, rater 
blinded parallel group 
 
Korea (single centre), 
hospital 
Janssen Korea 
Pharmaceutical 
Change from baseline in 
the PANSS-EC, CGI-S 
 
 
• 18 to 65 years  
• DSM-IV criteria for 
schizophrenia, 
schizoaffective disorder, 
bipolar 1, delusional 
disorder, psychotic disorder 
NOS 
• PANSS-EC score ≥14 with a 
score of  ≥4 on at least 5 
items and CGI-S score ≥3 
24 hours 
Meehan 
2001 
N=201 
 
Olanzapine IM  
doses 1and 2=10mg, dose 
3= 5 mg (n=99) 
Lorazepam  
doses  1and 2=2mg,  
dose  3= 1 mg (n=51) 
Placebo  
doses 1 and 2 = placebo, 
dose  3 = olanzapine 10mg 
(n=51) 
 
 
57 (58) 
 
 
21 (41)  
 
 
29 (57) 
 
 
Double blind, placebo 
controlled, parallel 
 
USA and Romania, 
setting not reported 
 
 
Eli Lilly 
 
(9 authors 
employed by Eli 
Lilly) 
Change from baseline in 
the PANSS-EC at 2hrs 
and 24hrs CGI-S 
 
 
• ≥18 years 
• DSM-IV criteria for bipolar 
disorder, manic or mixed, 
assessed as having  
agitation severe enough to 
be treated with injections 
• PANSS-EC score ≥14 with a 
score of  ≥4 on at least 1 
item 
24hrs 
Tran 
Johnson 
2007 
N=357 
 
Aripiprazole IM 1 mg (n=57) 
Aripiprazole IM  5.25mg 
(n=63) 
 
 
37 (65) 
 
35 (56) 
Double blind, placebo 
controlled, parallel 
 
Worldwide (30 centres 
in USA, 20 centres 
Bristol-Myers 
Squibb Otsuka 
Pharmaceuticals  
(1 author a 
consultant for 
Change from baseline in  
PANSS-EC at 2hrs 
 
 
• ≥18 years  
• appropriate for IM therapy 
for agitation 
• DSM-IV criteria for 
schizophrenia, 
24hrs 
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For Peer Review
Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Aripiprazole IM 9.75 mg 
(n=57) 
Aripiprazole IM  15 mg 
(n=58) 
Haloperidol IM 5.25 mg 
(n=60) 
Placebo doses 1 and 2= 
placebo, dose 3=  
aripiprazole IM 15mg 
(n=62) 
 
 
 
36 (63) 
 
35 (60) 
 
39 (65) 
 
 
32 (52) 
 
elsewhere) 
 
 
Bristol-Myers 
Squibb, 2 authors 
employed by 
Bristol- Myers 
Squibb, 2 authors 
employed by 
Otsuka 
Pharmaceuticals, 
one is stock 
shareholder in 
Bristol Myers 
Squibb as well as 
being a former 
employee) 
schizoaffective disorder, 
schizophreniform disorder, 
agitation severe enough to 
be treated with injections  
• PANSS-EC score ≥15  with 
a score of  ≥4 on at least 2 
items 
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Trial 
name 
Interventions 
Drug & dose, n 
Male % 
 
 
Study design location 
and setting 
Commercial 
support 
Outcomes Inclusion criteria Trial 
duration 
Wright 
2001 
N=311 
 
Olanzapine IM 10mg 
(n=131) 
 
Haloperidol IM 7.5mg 
(n=126) 
 
Placebo (n=54) 
 
 
Not 
reported 
 
Double blind, placebo 
controlled, parallel 
non-inferiority 
 
Australia, Austria, 
Belgium, Canada, 
Czech Republic, 
France, Greece, 
Hungary, Israel, South 
Africa, Spain, UK, USA 
Hospital 
Eli Lilly Change from baseline on 
PANSS-EC at 2 hours 
 
 
• ≥18 years 
• DSM-IV criteria for 
schizophrenia, 
schizoaffective disorder, 
schizophreniform disorder 
• agitation severe enough to 
be treated with injections  
• PANSS-EC score ≥14  with 
a score of  ≥4 on at least 1 
item 
24hrs 
Zhang 
2013 
N= 376 
 
Ziprasidone IM 
(n=189) 
 
Haloperidol IM 
(n-187) 
 
 
 
90 (47.6) 
 
 
89 (47.6) 
Rater-blind, active-
controlled, 
parallel-group, 
multicenter  
 
China 
 
Hospital 
Pfizer Change from baseline on 
BPRS at 72 hours 
 
Secondary: 
Change from baseline to 
2, 4, 24, 48, and 72 hours 
in BPRS agitation 
subscale 
 
• 18 to 65 years  
• ICD-10 criteria for 
schizophrenia, only those 
with acute phase of 
schizophrenia, who could 
receive IM medication for ≥3 
days 
• BPRS (1-7) score ≥40 and 
BPRS agitation subscale 
score ≥10, (≥3 score on at 
least 3 items) 
72 hours 
Zimbroff 
2007 
N=301 
 
Aripiprazole  IM 9.75mg 
(n=78) 
Aripiprazole IM 15mg 
(n=78) 
Lorazepam IM 2mg (n=70) 
 
Placebo IM  
 (n=75) 
 
 
 
157 (52) 
 
Double blind, placebo 
controlled, parallel 
non-inferiority 
 
Hospital 
 
Bristol-Myers 
Squibb and Otsuka 
Pharmaceutical  
(1 author had 
acted as 
consultant to 
Bristol- Myers 
Squibb, 4 were 
employees of 
Bristol-Myers 
Squibb and 2 were 
employees of 
Otsuka 
Pharmaceutical) 
Change from baseline on 
PANSS-EC at 2 hours 
 
 
• ≥18 years  
• DSM-IV criteria for bipolar 1 
disorder, manic or mixed, 
PANSS-EC score 15 to 32 
with a score of  ≥4 on at 
least 2 items 
 
 
24hrs 
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ACES=agitation calmness evaluation scale; BPRS=brief psychiatric rating scale; CGI-S=clinical global impressions (scale)-severity; DSM IV=diagnostic and statistical manual of mental disorders; 
ICD-10=international classification of diseases; IM=intramuscular; ODT=orally disintegrating tablet; PANSS-EC=positive and negative syndrome scale-excited component 
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Table 2 Trial outcomes 
Trial 
Interventions PANSS-EC 
SCORES 
(SD) 
Baseline 
Change in 
PANSS-EC 
SCORES 
(SD) 
30 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 60 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
120 min 
Change in 
PANSS-EC 
(SD) 
 
24 hours 
Any adverse 
events 
(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Allen 2011 Loxapine 
inhaled 10mg 
 
 
 
 
Loxapine 
inhaled  5mg 
 
 
 
Placebo inhaled 
 
 
17.32 (2.02) 
Range 14-21 
 
 
 
 
17.56 (1.94) 
Range 14-22 
 
 
 
17.72 (2.23) 
Range 14-24 
-6.51 (5.10) 
 
 
 
 
 
-5.71 (5.14) 
 
 
 
 
-4.21 (4.10) 
-7.46 (4.89) 
 
 
 
 
 
-6.69 (5.26) 
 
 
 
 
-5.02 (4.48) 
 
 
 
 
 
 
-8.39 (5.05) 
 
 
 
 
 
-6.56 (5.05) 
 
 
 
 
-5.26 (4.41) 
-8.56 (4.90) 
 
 
 
 
 
-6.71 (5.14) 
 
 
 
 
-4.98 (4.13) 
Not reported 
 
 
16/41 (39) 
Sedation (22%) 
Dysgeusia (17%) 
Throat irritation 
(7%) 
 
14/45  (31) 
Sedation (13% 
Dizziness (11%) 
Headache/Dysgeu
sia (4%) 
 
14/43  (33) 
Sedation (14%) 
Dysgeusia (9%) 
Dizziness (9%) 
 
No patient from any 
groups withdrew 
from the study due 
AEs 
Compared with placebo, 
statistically significant 
differences in efficacy were 
found for the 10mg dose in 
score change from baseline 
on the PANSS-EC 20 min 
after administration, 
continuing through 2 hours. 
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Trial 
Interventions PANSS-EC 
SCORES 
(SD) 
Baseline 
Change in 
PANSS-EC 
SCORES 
(SD) 
30 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 60 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
120 min 
Change in 
PANSS-EC 
(SD) 
 
24 hours 
Any adverse 
events 
(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Andrezina 
2006 
 
 
Aripiprazole IM  
n=175 
 
 
 
 
 
Haloperidol IM  
n=185 
 
 
 
 
Placebo  
n=88 
18.72 
 
 
 
 
 
 
18.79 
 
 
 
 
 
18.74 
 
-2.50 (SE 
0.45) 
 
 
 
 
 
-2.90 (SE 
0.45) 
 
 
 
 
-2.68 (SE 
0.53) 
-5.20 (SE 
0.55) 
 
 
 
 
 
-6.32  (SE 
0.55) 
 
 
 
 
-4.21 (SE 
0.65) 
-6.26 (SE 
0.57) 
 
 
 
 
 
-7.43 (SE 
0.57) 
 
 
 
 
-4.45 (SE 
0.67) 
-7.27 (SE 
0.59) 
 
 
 
 
 
-7.75 (SE 
0.59) 
 
 
 
 
-4.78 (SE 
0.69) 
-8.28 (SE 
0.50) 
 
 
 
 
 
-8.12 (SE 
0.50) 
 
 
 
 
-7.70 (SE 
0.59) 
52/175 
Headache (7.4%) 
Dizziness (6.3%) 
Nausea/insomnia 
(=5.7%) 
 
 
64/183 
Insomnia (12%) 
Headache (8.2%) 
EPD (5.5%) 
Agitation (4.4%) 
 
22/87 
Insomnia (9.2%) 
Headache (6.9%) 
Agitation (5.8%) 
 
 
3 patients 
discontinued  in 
total due to AEs 
Mean improvement in 
PANSS-EC at 2 hours was 
significantly greater for IM 
aripiprazole vs placebo. IM 
aripiprazole was non-inferior 
to IM haloperidol on 
PANSS-EC. 
Page 26 of 37
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Trial 
Interventions PANSS-EC 
SCORES 
(SD) 
Baseline 
Change in 
PANSS-EC 
SCORES 
(SD) 
30 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 60 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
120 min 
Change in 
PANSS-EC 
(SD) 
 
24 hours 
Any adverse 
events 
(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Breier 
2002 
Olanzapine IM 
2.5mg  n=48 
 
Olanzapine IM 
5.0mg   
n=45 
 
 
Olanzapine IM 
7.5mg  n=46 
 
Olanzapine IM 
10.0mg  n=46 
 
 
 
Haloperidol IM 
7.5mg 
n=40 
 
 
 
 
 
IM Placebo 
n=45 
18.3 (2.4) 
 
 
19.7 (3.4) 
 
 
 
 
18.9 (2.6) 
 
 
19.3 (2.6) 
 
 
 
 
19.3 (3.1) 
 
 
 
 
 
 
 
18.8 (2.8) 
 
Graph Graph Graph -5.5 (4.6) 
 
 
-8.1 (5.3) 
 
 
 
 
-8.7 (5.0) 
 
 
-9.4 (4.9) 
 
 
 
 
-7.5 (5.9) 
 
 
 
 
 
 
-2.9 (4.7) 
 
-4.9 (4.3) 
 
 
-5.5 (4.9) 
 
 
 
 
-5.5 (4.1) 
 
 
5.9 (5.2) 
 
 
 
 
-4.5 (4.0) 
 
 
 
 
 
 
-3.1 (3.3) 
Hypotension  2/48 
(4.2%) 
 
Hypotension 2/45 
(4.4%)  
Akathesia 2/42 
(4.8%) 
 
Hypotension: 1/46  
(2.2%) 
 
Hypotension: 2/46  
(4.3%) 
TE Parkinsonism: 
1/35 (2.9%) 
 
Acute dystonia: 
2/40 (5.0%) 
TE Parkinsonism: 
6/36 (16.7%) 
Akathesia: 3/38  
(7.9%) 
 
0 (0%) 
 
Total AEs not 
reported. No 
between-group 
differences 
observed. 
 
Withdrawals not 
reported 
All IM olanzapine doses and 
7.5mg of IM haloperidol 
were superior to IM placebo 
in reducing agitation (this 
effect was sustained with IM 
olanzapine for up to 24h), 
but IM olanzapine at 2.5mg 
was less effective than any 
of the other olanzapine 
doses or IM haloperidol, 
indicating a dose-response 
relationship across the IM 
olanzapine dose groups. 
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Trial 
Interventions PANSS-EC 
SCORES 
(SD) 
Baseline 
Change in 
PANSS-EC 
SCORES 
(SD) 
30 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 60 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
120 min 
Change in 
PANSS-EC 
(SD) 
 
24 hours 
Any adverse 
events 
(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Currier 
2004 
 
 
Risperidone 
+lorazepam 
(oral) 
N= 83 
 
Haloperidol + 
lorazepam IM 
N=79 
19 (3.0) 
 
 
 
 
19.1 (3.0) 
Graph Graph NR Graph NR 1 (1) 
 
 
 
 
1 (1) 
 
 
 
 
There were no 
significant between-
group differences in 
the incidence of any 
AE. 
1 patient from each 
group discontinued 
medication due to 
AE. 
A single dose of risperidone 
plus lorazepam was 
significantly as effective as 
IM haloperidol plus 
lorazepam at each time 
point for the rapid control of 
psychotic agitation. 
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Trial 
Interventions PANSS-EC 
SCORES 
(SD) 
Baseline 
Change in 
PANSS-EC 
SCORES 
(SD) 
30 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 60 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
SCORES 
(SD) 
120 min 
Change in 
PANSS-EC 
(SD) 
 
24 hours 
Any adverse 
events 
(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Fang  
2012 
Risperidone 
oral 2-6 ml plus 
Clonazepam 0-
8 mg per day  
 
 
 
 
Haloperidol IM 
10-20mg per 
day  
 
21.4 (4.6) 
 
 
 
 
 
 
 
22.5 (4.7) 
NR NR NR -7.5 (8.5) 
 
 
 
 
 
 
 
-8.0 (9.0) 
4.0 (5.6) 
 
 
 
 
 
 
 
-4.3 (5.9) 
 
39/104 (37.5) 
Akathisia 29 
(27.9%) 
EPS 26  (25%) 
Tachycardia 
(3.8%) 
Insomnia 4 (3.8%) 
 
65/101 (64.4) 
Akathisia 46 
(45.5%) 
EPS 56 (55.4%) 
Tachycardia 6 
(5.9%) 
Insomnia 6 (5.9%) 
No withdrawals  
Significant improvements 
were seen at 2, 4, 24h in 
both treatment groups, 
between-treatment 
differences in mean change 
scores on the PANSS-EC. 
Hsu 2010 
 
 
Olanzapine IM 
N=11 
 
 
Olanzapine 
ODT N=10 
 
Risperidone 
oral N=10 
 
 
Haloperidol IM 
N=11 
25.55 (3.8) 
 
 
 
24.7 (5.01) 
 
 
25.0 (2.58) 
 
 
 
28.18 (2.82) 
14.45(4.80) 
 
 
 
13.90(5.80) 
 
 
16.20(4.26 
 
 
 
20.36(5.2) 
? 
10.91(4.23) 
 
 
 
10.60(4.43) 
 
 
12.30(3.16) 
 
 
 
14.55(3.53) 
 
8.73(3.69) 
 
 
 
10.70(4.92) 
 
 
10.10(3.51) 
 
 
 
12.00(5.12) 
 
8.36(4.43) 
 
 
 
11.10(6.82) 
 
 
9.10(2.84) 
 
 
 
9.73(3.69) 
7.18(2.52) 
 
 
 
10.10(5.72) 
 
 
10.60(9.49) 
 
 
 
10.18(5.60) 
9/11 
 
 
 
6/10 
 
 
3/10 
 
 
 
4/11 
 
Withdrawals not 
stated 
Olanzapine IM or olanzapine 
ODT had significantly 
greater improvement in 
PANSS-EC scores than 
haloperidol IM at points 15, 
30, 45, 60, 75 and 90min 
after initiation of treatment 
(no significant differences 
between olanzapine IM and 
risperidone, olanzapine ODT 
and risperidone, risperidone 
and haloperidol IM, or 
olanzapine IM and 
olanzapine ODT at these 
time points). 
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(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Hwang 
2012 
Olanzapine IM 
10mg  
(n=37) 
 
Haloperidol IM 
5 mg and 
Lorazepam IM 
2mg 
(n=30) 
21.0 (4.6) 
 
 
 
20.9 (3.6) 
NR NR NR -10.0 (6.5) 
 
 
 
-9.8 (5.6) 
-9.1(5.5) 
 
 
 
-8.1(3.1)  
No severe AEs 
were noted and 
EPS were observed 
in 2 patients in the 
haloperidol group 
The PANSS-EC scores 
decreased significantly at 2 
hours within both groups, 
but there was no significant 
difference between the two 
groups (p = 0.890). 
 
There were no significant 
differences in PANSS-EC or 
ACES scores between the 
two groups at 15, 30, 60 
minutes and 24 hours. 
Katagiri 
2013 
Olanzapine IM 
N=45 
 
Placebo IM 
N=44 
23.5 (6.1) 
 
 
23.3 (4.9) 
NR NR NR -9.2 (4.5) 
 
 
-2.8 (5.6) 
-5.6 
 
 
-2.8 
13 (28.9) 
 
 
6 (13.3) 
 
no deaths or AEs 
leading to 
discontinuation 
At the 2 hour 
timepoint, the IM olanzapine 
group showed a significant 
decrease in all PANSS-EC 
individual item scores 
compared with the IM 
placebo group (p <.001). 
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PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
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PANSS-EC 
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(number, total,%) 
 
(3 most frequent 
are listed where 
known) 
 
Conclusion 
Kinon 
2004 
Olanzapine oral 
N=52 
 
 
 
 
Haloperidol  
Oral 
N=48 
38.30 (6.80) 
 
 
 
 
 
37.17 (6.32) 
 
NR Graph NR 
  
NR Graph  35/52 (67.5) 
Somnolence 
(17.3%) 
Anxiety (11.5%) 
Headache (11.5%) 
 
41/48 (85.4) 
Somnolence (25%) 
Headache (25%) 
Nervousness 
(16%) 
 
 
8/48 (16.7%) 
haloperidol 
discontinued 
1/52 (1.9%) 
olanzapine 
discontinued 
Significant within group 
improvement was shown in 
PANSS scores for both 
groups as early as 1h after 
initiating treatment. At the 
end of the study, the 
olanzapine group 
experienced significantly 
greater improvement than 
the haloperidol group in 
mean PANSS agitation 
scores.  
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(3 most frequent 
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known) 
 
Conclusion 
Kwentus 
2012 
Loxapine 
inhaled 5mg 
 
 
 
Loxapine 
inhaled 10mg 
 
 
 
 
Placebo inhaled 
17.4 (2.23) 
 
 
 
 
17.27 (2.25) 
 
 
 
 
 
17.74 (2.80) 
-7.54  (4.74) 
 
 
 
 
-7.99 (4.67) 
 
 
 
 
 
-3.88 (4.37) 
-8.78 (4.74) 
 
 
 
 
-8.80 (4.49) 
 
 
 
 
 
-4.96 (4.58) 
-8.29 (4.66) 
 
 
 
 
-8.85 (4.74) 
 
 
 
 
 
-4.99 (4.33) 
-8.1 (4.90) 
 
 
 
 
-9.0  (4.67) 
 
 
 
 
 
-4.9 (4.77) 
Not reported 
 
 
36/104 (34.6) 
Dysgeusia (17.3) 
Sedation (6.7%) 
Dizziness (5.8%) 
 
30/105  (28.6) 
Dysgeusia (17.1) 
Sedation (5.7%) 
Dizziness (4.8%) 
 
 
24/105 (22.9) 
Headache (8.6%) 
Dizziness (7.6%) 
Dysgeusia (5.7%) 
 
2 from 10mg group 
withdrew due to AE 
Both doses of inhaled 
loxapine significantly 
reduced agitation compared 
with placebo. 
Lesem 
2011 
Loxapine 
inhaled 5mg 
 
 
 
Loxapine 
inhaled 10mg 
 
 
 
Placebo inhaled 
17.83(2.34) 
 
 
 
 
17.59 (2.34) 
 
 
 
 
17.36(1.80) 
-6.78 (4.74) 
 
 
 
 
-7.61 (4.72) 
 
 
 
 
-4.15 (4.06) 
-7.67 (4.74) 
 
 
 
 
-9.16 (4.41) 
 
 
 
 
-5.23 (4.78) 
-8.23 (4.88) 
 
 
 
 
-9.12 (4.26) 
 
 
 
 
-5.33 (4.66) 
-8.1 (5.17) 
 
 
 
 
-8.6 (4.37) 
 
 
 
 
-5.5 (4.37) 
Not reported 
 
40/116 (30.5%) 
Sedation (12.9%) 
Dygeusia (8.6%) 
Dizziness (5.2%) 
 
43/113 (38.1%) 
Sedation (10%) 
Dygeusia (10%) 
Dizziness (10%) 
 
44/115 (38.3%) 
Headache (13.9%) 
Sedation (9.6%) 
Dizziness (9.6%) 
1 withdrawal 
(10mg) 
Loxapine 5mg and 10mg 
significantly reduced 
agitation compared with 
placebo.  
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Lim 2010 
 
Risperidone 
ODT 2mg 
 
 
 
 
 
Haloperidol IM 
5mg 
21.2 (3.0) 
 
 
 
 
 
 
21.5 (3.3) 
Graph only Not measured Not measured Graph only NR 17/62(27.4) 
Somnolence 
(14.3%) 
Insomnia (9.3%) 
EPS (8%) 
1/62 discontinued 
 
EPS (12.9%) 
Somnolence (11%) 
Headache (7%) 
8/62 (29.0) 
2/62 discontinued 
treatment 
The PANSS-EC and 
CGI-S scores were 
significantly decreased over 
time in both treatment 
groups without any 
significant group difference 
and time by group 
interaction effect 
Meehan 
2001 
 
Olanzapine IM  
 
 
 
 
 
Lorazepam 
 
 
 
 
Placebo 
 
12.96 (3.18) 
 
 
 
 
 
12.39 (2.97) 
 
 
 
 
12.72 (3.10) 
Not reported Not reported Not reported -9.60 (4.74) 
 
 
 
 
 
-6.75 (5.20) 
 
 
 
 
-4.84 (4.66) 
-5.78 (4.72) 
 
 
 
 
 
-5.65 (5.20) 
 
 
 
 
-3.94 (4.32) 
34/99 (34.3%) 
Somnolence 
(13.1%) 
Dizziness (9.1%) 
Dry mouth (3%) 
 
26/51 (51%) 
Dizziness (13.7%) 
Somnolence 
(9.8%) 
 
13/51 (25.5%) 
Somnolence 
(5.9%) 
Dizziness (2%) 
 
No deaths. 
Withdrawals not 
reported 
At 2 hours after the first 
injection, patients with 
olanzapine showed a 
significantly greater 
reduction in scores on all 
agitation scales compared 
with patients treated with 
either placebo or lorazepam. 
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(3 most frequent 
are listed where 
known) 
 
Conclusion 
Tran 
Johnson 
2007 
 
 
Aripiprazole IM 
1mg 
 
 
 
 
 
Aripiprazole IM 
5.25 mg 
 
 
 
 
Aripiprazole IM 
9.75 mg 
 
 
 
 
Aripiprazole IM 
15 mg 
 
 
 
 
Haloperidol IM 
7.5mg 
 
 
 
 
Placebo IM 
19.16 
 
 
 
 
 
 
19.46 
 
 
 
 
 
19.44 
 
 
 
 
 
19.34 
 
 
 
 
 
18.89 
 
 
 
 
 
19.21 
Graph only Graph only Graph only Graph only Graph only 28/56 (50) 
Tachycardia 
(7.2%) 
Headache (7.1%) 
Dizziness (7.1%) 
Somnolence (5.4) 
 
 
30/62 (48.4) 
Headache (17.7%) 
Nausea (9.7%) 
Somnolence 
(8.1%) 
 
25/56 (44.6) 
Headache (10.7%) 
Nausea (10.7%) 
Tachycardia 
(7.1%) 
Somnolence 
(5.4%) 
Akathisia (5.4%) 
 
27/58 (46.6) 
Headache (13.8%) 
Dizziness (12.1%) 
Somnolence (10.3) 
 
 
28/57 (49.1) 
Somnolence(12.3
%) 
Akathisia (10.5%) 
Dizziness (7.0%) 
 
18/61 (29.5) 
Dizziness (6.6%) 
Somnolence (4.9%) 
Nausea (3.3%) 
 
No discontinuations 
Significantly greater 
reductions in PANSS-EC 
scores were observed at 2h 
with all doses of IM 
aripiprazole (except the 1mg 
dose) and IM haloperidol 
7.5mg compared with 
placebo. The  PANSS-EC -
defined response rate with 
IM aripiprazole 15mg was 
significantly greater than the 
placebo at 60min. the 
response rate at 120min 
with IM haloperidol was 
significant at 120min, but not 
at 60min. 
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PANSS-EC 
SCORES 
(SD) 
 90 min 
Change in 
PANSS-EC 
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(3 most frequent 
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known) 
 
Conclusion 
Wright 
2001 
 
Olanzapine IM 
10mg 
 
Haloperidol IM  
75mg 
 
Placebo IM 
18.4 (3.4) 
 
 
18.2 (3.2) 
 
 
18.4 (3.5) 
Graph only Graph only Graph only -7.7 (6.1) 
 
 
-7.6 (5.0) 
 
 
-3.6 (5.2) 
-6.5 (5.3) 
 
 
-6.7 (4.6) 
 
 
-3.1 (5.1) 
EPS 1 (0.8%) 
 
 
Acute dystonia 9 
(7%) 
 
EPS 7 (5.6%) 
 
 
Witdrawals not 
reported 
Both IM olanzapine and IM 
haloperidol reduced 
agitation significantly more 
than IM placebo. 
Zhang 
2013 
 
 
Ziprasidone IM 
(n=189) 
 
 
 
 
Haloperidol IM 
(n-187) 
 
BPRS  
 
56.7 (8.1)  
 
 
 
 
 
56.5 (8.1) 
Not measured Not measured Not measured Not measured Not measured  
 
54/189 (28.6) 
Dizziness 7 (3.7%) 
Somnolence 7 
(3.7%) 
EPS 4 (2.1%) 
2 discontinued 
 
116/187 (62.0) 
EPS 69 (36.9%) 
Dizziness 7 (3.7%) 
Somnolence 7 
(3.7%) 
5discontinued 
No deaths occurred 
For controlling agitation in 
schizophrenia in this 
Chinese study, ziprasidone 
had a favourable tolerability 
profile and comparable 
efficacy and safety 
compared to haloperidol. 
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(3 most frequent 
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known) 
 
Conclusion 
Zimbroff 
2007 
 
 
 
 
 
Aripiprazole IM 
9.75mg (75) 
 
 
 
 
Aripiprazole IM 
15mg (75) 
 
 
 
Lorazepam IM 
2mg (68) 
 
 
 
 
Placebo (73) 
 
 
 
Not reported 
 
 
 
Graph only 
 
 
 
Graph only 
 
 
 
Graph only 
 
 
 
Graph only 
 
 
 
NR 
133/291 (46) 
 
 
41/75 (55) 
Headache (14.7%) 
Insomnia (10.7%) 
Nausea(10.7%) 
Somnolence 
(8.0%) 
 
56/75 (75) 
Nausea (18.7%) 
Headache (17.3%) 
Dizziness 12%) 
 
24/69 (35) 
Sedation (11.6%) 
Dizziness (10.1%) 
Somnolence 
(7.3%) 
 
29/72 (40) 
Headache (12.5%) 
Insomnia (8.3%) 
Dizziness (5.6%) 
 
2 discontinuations: 
1 x 15mg 
aripiprazole 
1 x placebo 
IM aripiprazole 9.75 and 15 
mg are effective and well 
tolerated for acute agitation 
in bipolar disorder, although 
the low incidence of over-
sedation suggests a risk–
benefit profile for IM 
aripiprazole 9.75mg. 
ACES=agitation calmness evaluation scale; AE=adverse event; CGI-S=clinical global impressions (scale)-severity; EPS=extra-pyramidal symptoms; IM=intramuscular; ODT=orally disintegrating 
tablet; PANSS-EC=positive and negative syndrome scale-excited component 
Graph only =data presented graphically, but specific information not available. 
Page 36 of 37
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 3 Change in PANSS-EC SCORES at 60 and 120 minutes 
Treatment comparison 
Change in PANSS-EC score (95% CI) 
60 mins 120 mins 
Haloperidol vs Olanzapine 3.653 (-8.111, 15.43) 1.192 (-6.673, 8.992) 
Risperidone vs 
Olanzapine 1.373 (-9.983, 12.62) 0.7162 (-8.707, 10.39) 
Haloperidol -2.28 (-12.95, 8.223) -0.4753 (-9.588, 8.535) 
Placebo vs 
Olanzapine 5.712 (-16.86, 27.59) 5.393 (-1.408, 12.16) 
Haloperidol 2.059 (-17.32, 21.17) 4.202 (-3.804, 12.21) 
Risperidone 4.338 (-17.57, 25.88) 4.677 (-5.921, 15.27) 
Loxapine 5mg 
vs 
Olanzapine 3.096 (-20.98, 26.49) 2.949 (-7.755, 13.31) 
Haloperidol -0.5569 (-21.49, 20.27) 1.758 (-9.544, 13.19) 
Risperidone 1.723 (-21.81, 24.69) 2.233 (-11.28, 15.4) 
Placebo -2.616 (-10.67, 5.568) -2.444 (-10.65, 5.497) 
Loxapine 
10mg vs 
Olanzapine 2.327 (-22.03, 25.43) 1.867(-8.422, 12.12) 
Haloperidol -1.326 (-22.45, 19.25) 0.6754 (-10.24, 11.64) 
Risperidone 0.954 (-22.95, 23.68) 1.151 (-11.96, 14.09) 
Placebo -3.384 (-11.17, 4.3) -3.526 (-11.43, 4.237) 
Loxapine 5mg -0.7688 (-8.791, 7.425) -1.083 (-9.42, 7.223) 
Aripiprazole vs 
Olanzapine 4.453 (-19.54, 28.32) 2.615 (-16.19, 21.71) 
Haloperidol 0.8 (-20.18, 22.19) 1.424 (-16.89, 20.73) 
Risperidone 3.08 (-20.31, 26.85) 1.899 (-18.01, 22.48) 
Placebo -1.259 (-20.73, 17.88) -2.778 (-21.3, 16.35) 
Loxapine 5mg 1.357 (-19.43, 22.76) -0.3342 (-20.33, 19.68) 
Loxapine 10mg 2.126 (-18.73, 23.39) 0.7483 (-18.84, 20.96) 
Rispiradone + 
Clonazepam 
vs 
Olanzapine NR 1.038 (-23.6, 26) 
Haloperidol NR -0.1534 (-23.82, 23.87) 
Risperidone NR 0.3219 (-25.08, 26.1) 
Placebo NR -4.355 (-29.28, 20.65) 
Loxapine 5mg NR -1.911 (-28.48, 24.21) 
Loxapine 10mg NR -0.8288 (-26.88, 25.38) 
Aripiprazole NR -1.577 (-33.39, 28.92) 
Lorazepam vs 
Olanzapine NR 3.085 (-10.24, 16.16) 
Haloperidol NR 1.894 (-12.54, 16.28) 
Risperidone NR 2.369 (-13.8, 18.28) 
Placebo NR -2.308 (-15.21, 10.81) 
Loxapine 5mg NR 0.1359 (15.4, 15.16) 
Loxapine 10mg NR 1.218 (-14.06, 16.23) 
Aripiprazole NR 0.4701 (-22.34, 23,27) 
Rispiradone + 
Clonazepam 
NR 2.047 (-25.28, 29.89) 
Haloperidol + 
Lorazepam vs 
Olanzapine NR 0.1978 (-16.89, 17.7) 
Haloperidol NR -0.9937 (-20.14, 18.29) 
Risperidone NR -0.5184 (-20.23, 19.41) 
Placebo NR -5.196 (-23.33, 13.04) 
Loxapine 5mg NR -2.752 (-22.51, 17.22) 
Loxapine 10mg NR -1.669 (-21.61, 18.56) 
Aripiprazole NR -2.417 (-28.23, 22.29) 
Rispiradone + 
Clonazepam 
NR -0.8403 (-31.28, 29.24) 
Lorazepam NR -2.888 (-24.22, 18.89) 
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